We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative vaccines for a healthier world
Advancing groundbreaking vaccines through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.
Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.
ES2B-C001: Advancing HER2 Cancer Immunotherapy
At ExpreS2ion Biotech, we are transforming HER2 cancer immunotherapy with ES2B-C001, a novel vaccine built on our proprietary ExpreS2 platform for the efficient production of high-quality HER2 antigens. By combining these antigens with a virus-like particle (VLP) delivery system, ES2B-C001 effectively engages the immune system to generate a broad and durable antibody response. Targeting all four extracellular domains of the HER2 receptor, it offers superior tumour inhibition and resistance prevention compared to traditional monoclonal antibody therapies.
Watch the video below to learn more about this breakthrough approach.
Latest news
ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025
Hørsholm, Denmark, 13 November 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first nine months and third quarter 2025 results. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.
Read moreCorrection: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines
This press release is a correction to the press release made earlier this afternoon, which did not specify the aggregated milestones as being in EUR millions. Hørsholm, Denmark, 12 November 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases…
Read moreExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines
Hørsholm, Denmark, 12 November 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today announced the execution of a definitive licensing agreement with Serum Institute of India Pvt. Ltd. (“SII”) for two novel blood-stage malaria vaccines, RH5.1…
Read more